2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
LASE Corp. said its Board appointed Sanjay Adhav and Chief Financial Officer Timothy A. Peterman as directors, effective November 3, 2026, to fill two existing vacancies. The company announced the appointments in a press release dated November 9, 2026, and the filing discloses no related-party transactions or arrangements for either appointee.
Board appointed Sanjay Adhav and CFO Timothy A. Peterman as directors, effective November 3, 2026, filling two existing vacancies
Adhav has served as President of Quantum Technology, Inc. since 2013; Peterman was CEO of iMedia Brands, Inc. from 2019 to 2023
Press release announcing the appointments was issued November 9, 2026 (Exhibit 99.1)
TechPrecision and its subsidiaries Ranor and Stadco entered a $10.0 million credit agreement with Rosenthal & Rosenthal on November 3, 2026, and used the proceeds to repay the prior Beacon Bank & Trust loan agreement. The facility includes a revolving line of up to $5.0 million and two term loans, and it requires a minimum quarterly tangible net worth of $5.5 million. The company also said it may be unable to file its Form 10-Q for the period ended September 30, 2026 on time.
Facility includes a $5.0 million revolving line, a $1.5 million three-year term loan and a $3.5 million five-year term loan, secured by substantially all personal property and a first mortgage on Ranor's Westminster, Massachusetts facility
Prior Beacon Bank & Trust loan agreement was terminated and repaid in full on November 3, 2026; closing costs were approximately $0.6 million.
Company issued 25,000 shares of common stock to the broker that introduced the lender.
Management expects the financing to alleviate the substantial doubt about going concern; tangible net worth was $7.6 million as of June 30, 2026 against the $5.5 million covenant.
Reliance Global Group, Inc. (EZRA) closed its acquisition of the Oblivus GPU cloud computing platform on November 3, 2026, paying $3,000,000 in cash at closing from cash on hand, with up to $750,000 more in milestone payments that depend on future revenue. The company says Oblivus generated about $1.5 million in revenue for the twelve months ended September 2026, based on unaudited seller records, and that the deal marks its entry into the AI infrastructure market. Shareholders should note that the company has not yet filed the required acquired-business financial statements and pro forma information, and that its trading symbol is set to change to XGPU on November 10, 2026.
Closing payment of $3,000,000 in cash; up to two $375,000 milestone payments tied to average monthly cash revenue of $79,000 and $120,000
Oblivus reported about $1.5 million in revenue for the twelve months ended September 2026, per seller's unaudited records
Consulting agreement with founder Matthew Antoun: $250,000 in cash fees over 12 months, plus stock up to $600,000 subject to Board approval
Trading symbol expected to change from EZRA to XGPU on Nasdaq at the open on November 10, 2026
On November 6, 2026, U.S. GoldMining agreed to sell 408,163 common shares at $4.90 each to an institutional investor in a registered direct offering. Gross proceeds are expected to be about $2.0 million before offering expenses, with closing expected on or about November 9, 2026. The company plans to use the net proceeds for working capital and general corporate purposes.
Shares offered: 408,163 common shares at $4.90 per share
Expected gross proceeds: approximately $1,999,998.70 before offering expenses
Offering made under an effective Form S-3 shelf registration (File No. 333-279435) and a prospectus supplement dated November 6, 2026
Expected closing on or about November 9, 2026, subject to customary conditions
At its November 9, 2026 annual meeting, Lisata Therapeutics stockholders approved the 2026 Equity Incentive Plan, the 2026 Employee Stock Purchase Plan, and a reverse stock split authorization with a ratio between 1-for-5 and 1-for-15. The vote on the Series C preferred stock conversion proposal, which would exceed 20% of outstanding common stock and result in a change of control, was not held and the meeting was adjourned. The conversion vote will resume at a reconvened meeting on November 30, 2026.
2026 Equity Incentive Plan approved with an initial reserve of 44,764,472 shares; 2,924,154 votes for and 1,552,345 against.
2026 Employee Stock Purchase Plan approved with an initial reserve of 3,730,372 shares.
Reverse stock split proposal approved with a ratio to be set by the Board between 1-for-5 and 1-for-15; 7,524,706 votes for.
Series C preferred conversion proposal not voted; reconvened meeting set for November 30, 2026 at 11:00 a.m. Eastern.
DoubleVerify said it expects the merger under its August 6, 2026 agreement to close in the fourth quarter of 2026, subject to remaining closing conditions. Under the merger, DoubleVerify will survive as a wholly owned subsidiary of Neptune BidCo US Inc., so shareholders will be affected by the completion timing and terms of the deal.
Merger Agreement dated August 6, 2026, with Neptune BidCo US Inc. (Parent) and Wallace Merger Sub Inc. (Merger Sub)
Company expects closing during the fourth quarter of 2026, subject to satisfaction or waiver of remaining conditions
After the merger, DoubleVerify continues as the surviving corporation and a wholly owned subsidiary of Parent
Filing is made under Regulation FD and restates terms of a previously announced transaction
UWM Holdings Corporation announced the final subscription price for its rights offering of up to 200,000,000 Class A common shares: $2.00 per share. The price is the greater of $2.00 and 85% of the 10-day volume-weighted average NYSE sales price ending November 9, 2026, so the $2.00 floor applied. Subscription rights expire at 5:00 p.m. Eastern Time on November 12, 2026, unless extended.
Final subscription price is $2.00 per share, the greater of $2.00 and 85% of the 10-day volume-weighted average price ending November 9, 2026.
The rights offering covers up to 200,000,000 shares of Class A common stock.
Subscription rights expire at 5:00 p.m. Eastern Time on November 12, 2026, unless extended.
Exercised rights can be withdrawn until 5:00 p.m. Eastern Time on November 10, 2026, unless the offering is extended; the company may amend, withdraw or terminate the offering with consent of the Backstop Purchasers.
JBS N.V. agreed to acquire Flora Produtos de Higiene e Limpeza S.A., a Brazilian personal care and household products company, from its controlling shareholder J&F, in a transaction valued at US$542 million including assumed debt. JBS also agreed to buy Canal Rural, a Brazilian agribusiness media company, for R$88.1 million, and both deals are related-party transactions to be paid mainly in JBS Class A shares, which would add to the share count and dilute existing holders.
Flora: R$2.968 billion purchase price (US$542 million enterprise value); equity consideration of US$367 million to be paid in JBS Class A shares and/or BDRs
Canal Rural: R$88.1 million purchase price, paid to J&F in Class A shares; the Ex-99.1 release gives a US$11 million transaction value
Share issuance is based on a reference price of R$66.82916 per share (US$12.20 30-day volume-weighted average), with about 31.4 million treasury shares, or 2.9% of the share count, cited in the market presentation
Both agreements were signed November 9, 2026, and the transactions are expected to close in December 2026, subject to customary closing conditions
AGNT, Inc. entered into a Termination and Release Agreement with founder Glenn Sanford, effective retroactively to October 8, 2026, the date his employment ended in connection with the previously announced CEO transition. Sanford remains Chairman of the Board, and the agreement does not govern his board service. The release of claims is not yet effective, and the filing does not provide financial figures for the payments.
Separation Date is October 8, 2026; agreement signed November 9, 2026, and the release has not yet become effective.
Sanford keeps eligibility for eXp Realty revenue share at the highest front line qualifying agent tier, for as long as he holds Vested Status.
Company will pay or reimburse COBRA continuation coverage until the first anniversary of the Separation Date, subject to the release becoming effective.
A previously anticipated consulting agreement was not entered into; Sanford has no obligation to provide services.
Effective November 1, 2026, Matthew DiCanio became President and Chief Executive Officer, William K. Newton moved to Executive Chairman, and Tanner Newton became Executive Vice President and Chief Financial Officer. The filing also details new employment agreements and restricted stock grants to named executive officers, which set severance and change-in-control terms for shareholders to weigh.
Matthew DiCanio: President and CEO, base salary $785,000, target bonus 125% of base salary
William K. Newton: Executive Chairman, base salary $550,000, target bonus 85% of base salary
Tanner Newton: EVP and CFO, base salary $425,000, target bonus 75% of base salary
Restricted stock granted November 3, 2026 vests equally over four years; DiCanio received 164,894 shares
American Tower priced three registered senior unsecured note offerings totaling $1.5 billion on November 9, 2026. The notes are fungible with existing notes issued on September 14, 2026, and expected net proceeds are $1,474.9 million, which the company intends to use to repay borrowings under its $6.0 billion revolving credit facility and for general corporate purposes.
2031 notes: $450.0 million at a 5.300% interest rate, priced at 99.387% of face value
2033 notes: $500.0 million at a 5.560% interest rate, priced at 99.369% of face value
2036 notes: $550.0 million at a 5.750% interest rate, priced at 98.986% of face value
Expected net proceeds of $1,474.9 million, to repay revolver borrowings and for general corporate purposes
NIKE appointed Dan McKenzie as Vice President, Chief Accounting Officer, Finance Operations & Transformation, and principal accounting officer, effective November 9, 2026. As of the same date, CFO David Denton stops serving as Interim Corporate Controller and principal accounting officer. McKenzie retired from NIKE in July 2026 and returns under an offer letter dated November 4, 2026.
McKenzie's pay under the offer letter: $500,000 base salary, 50% target annual bonus, and a $525,000 annual long-term incentive target.
McKenzie will receive a $600,000 target-value sign-on RSU award that vests in three equal annual installments.
David Denton, Executive Vice President and CFO, ceases as Interim Corporate Controller and principal accounting officer effective November 9, 2026.
McKenzie previously served as VP, CFO, Global Operations and Technology from August 2025 to July 2026, and spent more than 19 years at NIKE.
Forge Nano Holdings said it completed its merger with HzO, Inc. on November 4, 2026, with HzO surviving as a wholly owned subsidiary. HzO stockholders were issued Forge Nano common stock as consideration, and part of that stock is held back for twelve months to secure post-closing adjustments and indemnification. The filing adds dilution from the new shares, but it does not provide HzO financial results or the effect on Forge Nano's earnings.
Merger consideration is based on a $55.0 million base purchase price, plus or minus closing cash, working capital, indebtedness and expense adjustments, divided by $10.00 per share.
Forge Nano issued 5,772,645 shares at the Effective Time, with 1,533,795 Holdback Shares held back for twelve months.
Shares received by HzO stockholders are locked up until the earlier of six months after the Effective Time or when the stock closes at or above $12.00 for 20 of 30 trading days.
HzO's CFO Jason Savod and President and COO Rachael Lerebours signed employment agreements with Forge Nano effective after the Effective Time.
Pangaea Logistics Solutions chair Richard T. du Moulin notified the Board on November 3, 2026, that he will retire as a director effective December 31, 2026. He has served on the Board since the company's 2014 IPO, and the filing says his affiliation with the company dates back more than 25 years. The filing does not name a successor.
Retirement notified to the Board on November 3, 2026, effective December 31, 2026
Du Moulin has served as a director since Pangaea's 2014 IPO and was affiliated with the company for more than 25 years
Claus Boggild, a founder and Lead Independent Director, praised his knowledge, forethought and integrity
GeoVax Labs appointed Tyler O'Brien as interim Chief Executive Officer and Chairman of the Board effective November 8, 2026, and added Shahin Behroyan as a director effective November 5, 2026. The filing follows the resignation of five former directors effective October 23, 2026, and it references a dispute over the termination of a former executive, Mr. Dodd, for Cause, which the company says could lead to severance or litigation. Shareholders face a leadership change at the top of the company while a permanent CEO is sought.
Tyler O'Brien appointed interim CEO and Chairman of the Board effective November 8, 2026; will serve until a permanent principal executive officer is appointed or designated
Shahin Behroyan appointed to the Board effective November 5, 2026, to fill a vacancy from the resignation of five former directors effective October 23, 2026
Behroyan is not yet on any committee; Board determined he is independent under Nasdaq Rule 5605(a)(2)
Forward-looking statements cite a possible dispute with Mr. Dodd over termination for Cause, with potential severance of three times base salary and target bonus
KBR said its lead independent director, Wendy Masiello, and director Nchacha Etta will retire from its board, and Executive Vice President Mark Sopp will retire from the company, all effective upon completion of the planned Trinzic spin-off. KBR also announced the expected Trinzic board, with Masiello as chair and Michael LaRouche as president and CEO-designate, and the spin-off is targeted for January 4, 2027, subject to final board approval.
Masiello (Lead Independent Director) and Etta (board member) notified KBR on November 5, 2026 of their retirements, effective upon completion of the spin-off
Sopp, Executive Vice President, Strategic Transactions, notified KBR on November 6, 2026 of his retirement and will receive no severance payments or benefits
KBR said the retirements were not the result of any disagreement with KBR on its operations, policies or practices
The spin-off is targeted for January 4, 2027, and Trinzic's board will have eight members, with Masiello as chair
Upstart's Chief Accounting Officer and Principal Accounting Officer, Natalia Mirgorodskaya, informed the company on November 3, 2026 that she will resign effective November 30, 2026, to pursue another opportunity. The company said the resignation does not stem from any disagreement over its operations, policies or practices, and CFO Andrea Blankmeyer will serve as Interim Principal Accounting Officer while a permanent replacement is sought.
Natalia Mirgorodskaya's resignation takes effect November 30, 2026; she informed the company on November 3, 2026.
The filing states the resignation is not due to any disagreement with the company on operations, policies or practices.
CFO Andrea Blankmeyer becomes Interim Principal Accounting Officer upon the resignation; her compensation is not being adjusted.
The company is conducting a search for a permanent replacement; no successor is named in the filing.
On November 9, 2026, Humana Inc. announced cash tender offers for eight series of its outstanding senior notes, with an aggregate purchase cap of $1.5 billion excluding accrued coupon payments. The offers expire at 5:00 p.m. New York City time on November 16, 2026, with settlement expected November 18, 2026. The filing is a debt management action and does not state its effect on earnings or guidance.
Aggregate purchase cap of $1.5 billion, excluding accrued coupon payments, subject to proration and acceptance priority levels
Series cap of $800 million on the 5.375% Senior Notes due 2031
Offers expire 5:00 p.m. New York City time on November 16, 2026; pricing is set on the same day at 3:00 p.m.
Expected settlement date is November 18, 2026; dealer managers include Barclays, BofA Securities, PNC and U.S. Bancorp
On November 9, 2026, Equinix Europe 2 Financing Corporation, an indirect wholly-owned subsidiary, issued €2.5 billion of senior notes in four series, fully and unconditionally guaranteed by Equinix, Inc. The notes carry fixed coupons from 4.150% to 5.450% and mature between 2028 and 2038, and Equinix intends to allocate the proceeds to eligible green projects. For shareholders, this adds debt to the company's balance sheet, though the filing does not compare it with existing debt levels.
€650 million 4.150% notes due November 9, 2028, and €700 million 4.800% notes due February 15, 2033
€500 million 5.100% notes due November 9, 2035, and €650 million 5.450% notes due November 9, 2038
Net proceeds are intended for eligible green projects; pending allocation, they may be held in cash or used to repay existing borrowings
Equinix hedged part of the interest rate risk on the 2035 and 2038 notes, with effective all-in rates of 4.91% and 5.42%
AH Realty Trust founder Daniel Hoffler resigned from its board of directors, and the board appointed David Hirsh as an independent director to fill the vacancy. The 8-K says Hoffler's resignation was not due to any disagreement with the company, and the press release says both changes took effect November 6, 2026.
Daniel A. Hoffler, the company's founder, resigned from the board; the 8-K says he informed the board on November 5, 2026 and the resignation was effective immediately
The press release says Hoffler retired effective November 6, 2026
David Hirsh, age 63, was appointed an independent director and will serve until the 2027 annual meeting of stockholders
Hirsh has not been named to any board committees; he previously spent about 16 years at Blackstone Inc., retiring in January 2018
Cannae Holdings released its third quarter 2026 results on November 9, 2026, posting them on its website and in a shareholder letter, with a conference call scheduled for 5:00pm Eastern that day. The letter highlights a 70% drop in holding company expenses, $111 million of year-to-date share buybacks, and $793 million of proceeds from noncore asset sales since the start of 2025, though the excerpt does not state consolidated third quarter revenue, profit or per-share figures.
Holding company expenses fell $58.8 million, or 70%, in the first nine months of 2026 compared with 2025.
Year to date in 2026, Cannae repurchased 7.7 million shares for $111 million, representing 16.4% of shares outstanding, and paid $20 million in dividends.
Proceeds from noncore asset sales totaled $793 million from the beginning of 2025 through the third quarter of 2026.
Two directors will not stand for re-election at the December 11, 2026 annual meeting, and the board will shrink to ten members afterward.
Stryker's board increased its size from 11 to 12 directors and elected James E. Davis, CEO and President of Quest Diagnostics, to fill the new seat. The election takes effect January 1, 2027, and Davis has not yet been assigned to any board committee.
Board expanded from 11 to 12 authorized directors on November 3, 2026
James E. Davis, CEO and President of Quest Diagnostics since November 2022, elected to fill the vacancy effective January 1, 2027
Davis will receive non-employee director compensation consistent with other directors and will sign the company's standard director indemnification agreement
No financial results or guidance were included in the filing
Valor Energy entered an amendment to its equity transfer agreement with Glorious Star, LLC for the Youngstown Computing Center, changing how the $360,000 deposit is handled and setting a closing deadline. The filing states the remaining purchase price is payable at closing and that any additional power capacity would be a separate transaction requiring its own agreement, which does not affect the closing obligations.
Purchase price is $3,600,000; the $360,000 deposit is now paid directly to the seller after Valor confirms due diligence and its Initial Valuation are satisfactory, replacing escrow
Payment is a generally non-refundable down payment credited toward the price, subject to refund provisions in the amendment
Closing is due by the thirtieth Business Day after the original October 18, 2026 effective date, unless extended in writing
Amendment dated November 3, 2026; filed November 9, 2026 as Exhibit 10.1
Genworth Financial said its Vice President and Controller, Darren W. Woodell, resigned to pursue a new opportunity, and the board appointed Chief Financial Officer Jerome T. Upton as interim Principal Accounting Officer effective November 6, 2026. The filing also notes Upton will become President and Chief Executive Officer effective January 1, 2027, following the retirement of Thomas J. McInerney.
Darren W. Woodell resigned as Vice President and Controller; the company accepted the resignation on November 6, 2026.
Jerome T. Upton, currently Executive Vice President and Chief Financial Officer, serves as interim Principal Accounting Officer until a permanent appointment is made.
Upton's compensatory arrangements will not change because of the accounting role.
Upton is slated to become President and Chief Executive Officer on January 1, 2027, when Thomas J. McInerney retires, as announced October 30, 2026.
Orchestra BioMed sold 15,000,000 shares of common stock at $5.00 per share under an underwritten public offering priced November 5, 2026, and the offering closed November 9, 2026. The underwriters' 2,250,000-share option was exercised in full on November 6, 2026, and the filing puts gross proceeds at approximately $86.3 million before underwriting discounts and expenses, with the company citing the AVIM Therapy program, the BACKBEAT pivotal trial, and the Virtue SAB program as intended uses.
Offering: 15,000,000 shares at $5.00 per share, priced November 5, 2026, with Piper Sandler and TD Securities as representatives of the underwriters
Underwriters' 30-day option for 2,250,000 additional shares was exercised in full on November 6, 2026
Gross proceeds of approximately $86.3 million before underwriting discounts, commissions and other offering expenses; offering closed November 9, 2026
Stated uses: AVIM Therapy program, BACKBEAT global pivotal trial, Virtue SAB program and its coronary in-stent restenosis trial, other product candidates, and working capital
Pathward Financial's Compensation Committee approved a $340,923 cash payment to Anthony Sharett, who resigned as President effective October 23, 2026. The payment recognizes his annual incentive award for fiscal 2026, which he would not otherwise have received because of his departure. The payment depends on his signing an acknowledgement, and the company plans to file it with its 10-K if he does.
Committee approved the $340,923 payment on November 3, 2026.
Payment is tied to the fiscal year ended September 30, 2026, based on predetermined performance measures and an individual discretionary component.
Sharett stopped being employed by the company and Pathward on October 23, 2026.
Payment is subject to Sharett signing an acknowledgement; the company intends to file it with its 10-K if executed.
MVB Financial Corp. entered into restated employment agreements dated November 5, 2026 with Craig B. Greathouse, Michael R. Sumbs, Michael L. Giorgio and Joseph R. Rodriguez. The agreements supersede prior contracts, update base salaries, and revise severance terms, including a lump-sum payment of 2.0 times salary plus target bonus after a termination without cause tied to a change in control. Rodriguez's title changed from Chief Risk Officer to EVP, Chief Legal Officer and Corporate Secretary.
Base salaries: $400,000 for Greathouse, $400,000 for Sumbs, $425,000 for Giorgio and $416,000 for Rodriguez.
Termination without cause, no change in control: 12 months of base salary, up to 12 months of COBRA premium coverage, and a pro-rated annual bonus.
Termination without cause tied to a change in control: lump sum of 2.0 times annualized base salary plus target annual bonus, and up to 24 months of COBRA coverage.
Rodriguez's title changed to EVP, Chief Legal Officer and Corporate Secretary.
Hims & Hers expanded its board from nine to ten directors and appointed Dr. Andrew Huberman, 51, effective immediately, as a director who is not independent under NYSE standards. The same week, the company's subsidiary agreed to pay Dr. Huberman a $3.5 million annual advisory fee and a separate company agreement pays his media company, Scicomm Media, $5 million a year, a related-party arrangement that shareholders may weigh against the board seat.
Dr. Andrew Huberman, 51, appointed to the board on November 4, 2026, filling a newly created seat; not on any committee.
Advisory Agreement dated November 5, 2026: $3,500,000 annual cash fee for two years, plus up to $1,000,000 per year for short-form videos.
Marketing Agreement with Scicomm Media LLC, co-owned by Dr. Huberman: $5,000,000 annual fee for up to three years; his interest is about $2,100,000 annually.
Director cash retainer of $50,000 and equity award valued at $250,000, prorated through the 2027 annual meeting.
Texas Instruments completed the sale of $2 billion of senior notes on November 9, 2026, split into four $500 million tranches maturing in 2028, 2031, 2033 and 2036. The filing is a debt financing that adds to the company's borrowings, and it sets coupons of 5.000% to 5.750%, which shareholders may weigh against the cost of that debt.
Four $500 million tranches: 5.000% notes due 2028, 5.350% due 2031, 5.500% due 2033 and 5.750% due 2036
Sold under an underwriting agreement dated October 26, 2026 with J.P. Morgan Securities LLC, Citigroup Global Markets Inc., BofA Securities, Inc. and U.S. Bancorp Investments, Inc. as representatives
Issued under a 2011 indenture with U.S. Bank Trust Company, National Association, as trustee, and offered under a Form S-3 filed February 14, 2025
Park Dental Partners closed its acquisition of the dental services organization supporting Village Family Dental on November 6, 2026, expanding into North Carolina, its fourth state. Base consideration was approximately $39.1 million, including 474,535 restricted shares valued at about $9.2 million, with potential aggregate consideration of up to about $46.0 million including earnouts. The company said the transaction's financial impact, including on 2026 guidance, will be shared with its earnings release on November 12, 2026.
Closed November 6, 2026; the transaction was first disclosed August 10, 2026, and adds 12 practice locations and 47 doctors.
Base consideration of approximately $39.1 million, with up to $4.6 million EBITDA-based contingent consideration and up to $2.3 million employment-contingent consideration.
Credit agreement amended to raise the maximum revolving commitment from $15.0 million to $25.0 million and add the North Carolina subsidiary as a co-borrower.
Company will release earnings November 12, 2026, with a call on November 13, and will address the transaction's impact on 2026 guidance then.
Kustom Entertainment amended its Unit Purchase Agreement to acquire TFL, LLC, extending the outside termination date from October 15, 2026 to December 18, 2026. The amendment also sets expense payment and reimbursement terms for the Sellers, and the closing remains subject to third-party consents, stockholder approvals, and other customary conditions.
Outside termination date moved from October 15, 2026 to December 18, 2026
If the deal does not close by December 18, 2026, Kustom will pay the Sellers' eligible expenses incurred after November 16, 2026
If the agreement is terminated, Kustom will reimburse up to $200,000 of Sellers' costs for an incremental audit within five business days
On November 9, 2026, CRH America Finance, a wholly owned subsidiary of CRH plc, completed the sale of four series of U.S. dollar guaranteed notes, fully guaranteed by CRH plc, with principal amounts totaling $4.2 billion. The company said net proceeds are expected to fund tender offers for outstanding Arcosa, Inc. notes, repay existing debt and support general corporate purposes, which adds to CRH's debt obligations while refinancing and reshaping its borrowings.
Four series issued: $1.35 billion 5.375% notes due 2032, $1.0 billion 5.625% notes due 2034, $1.35 billion 5.750% notes due 2037, and $500 million 6.250% notes due 2057
Notes were sold under an underwriting agreement dated November 4, 2026, with Barclays Capital, J.P. Morgan Securities and Morgan Stanley as representatives
Net proceeds are expected to finance tender offers for Arcosa, Inc. notes, repay existing debt and fund general corporate purposes
RPM presented its MAP 2030 operating improvement program at an Investor Day in Cherry Hill, New Jersey, on November 9, 2026. The company set fiscal 2030 targets of $10 billion in revenue, $2 billion in adjusted EBITDA, a 20% adjusted EBITDA margin and a $30 billion market capitalization, up from fiscal 2026 net sales of $7,863 million and adjusted EBITDA of $1,228 million (15.6% margin).
Fiscal 2026 net sales were $7,863 million, with adjusted EBITDA of $1,228 million, a 15.6% margin.
Fiscal 2030 targets include $10 billion in revenue and $2 billion in adjusted EBITDA, a 20% margin.
The presentation is attached as Exhibit 99.1, and the Investor Day event will be recorded with a replay on the company website.
The company did not provide a reconciliation of its fiscal 2030 adjusted EBITDA target to GAAP, citing terms outside its control.
Oppenheimer Holdings subsidiary Viner Finance entered into a lease on November 5, 2026, for about 221,339 rentable square feet at 32 Old Slip in Lower Manhattan, to serve as the firm's principal New York City offices. Fixed annual rent is approximately $13.3 million for the first five years after rent commencement, rising in later periods, and the company expects significant additional capital spending for furniture, equipment and technology tied to the relocation.
Lease covers about 221,339 rentable square feet with an initial term of approximately 15.5 years.
Rent commencement is the later of six months after final delivery of the Premises and July 1, 2028; fixed rent is about $13.3 million a year for the first five years, $14.4 million for the next five, and $15.5 million thereafter.
Viner has an option to terminate at the tenth anniversary of rent commencement for a termination fee of a maximum aggregate of approximately $24 million.
Oppenheimer's press release says phased move-in is targeted to begin in the first quarter of 2028.
Exascale Labs countersigned a $9.04 million firm purchase order for 16 Intel BHS 10U GPU servers with NVIDIA HGX B300 GPUs from Compal Electronics. The filing also describes a framework that would let the company buy up to 128 servers in total, but it places no minimum purchase obligation on the company, and the second order has not been placed. The filing does not describe financial results, and it is not clear how the servers will be funded or used.
Purchase covers 16 servers at $565,000 each, for an aggregate price of $9,040,000 excluding taxes
Down payment of $1,808,000 (20%) due within five business days of Compal's written order confirmation; remaining $7,232,000 (80%) due before shipment
Framework allows purchases of up to 128 servers through March 31, 2027, with no minimum commitment; no order has been placed under the second framework agreement
Company agreed to a storage arrangement and a three-year warranty from Compal; Compal and the company are described as unaffiliated
Werewolf Therapeutics released early clinical data for its two INDUKINE candidates, WTX-124 and WTX-330, presented at the Society for Immunotherapy of Cancer's 2026 Annual Meeting. The company said it has aligned with the FDA on an 18 mg IV Q2W recommended Phase 2 dose for WTX-124 and that WTX-330 was well tolerated. The filing contains no financial results, and the data come from small early-stage trials, so shareholders will mainly weigh the programs' future development prospects.
WTX-124 recommended Phase 2 dose set at 18 mg IV Q2W, aligned with the FDA, for monotherapy and combination with pembrolizumab
WTX-124 monotherapy produced one durable confirmed complete response in a patient with ICI-resistant cutaneous squamous cell carcinoma, ongoing for approximately three years
WTX-330 data from 24 patients showed a confirmed partial response in a patient with gallbladder cancer, per the filing
TMC USA, a subsidiary of TMC the metals Co Inc., received a letter from NOAA stating it expects to notify TMC USA of its final determination on certification of its consolidated application for an exploration license and commercial recovery permit by mid-December 2026. The filing notes the timing is an estimate, DSHMRA sets no mandatory deadline, and certification is an intermediate step that is not an approval or issuance of a license or permit.
NOAA letter received by TMC USA on November 3, 2026
NOAA expects to notify TMC USA of its final determination on certification by mid-December 2026
Application covers an exploration license and a commercial recovery permit under DSHMRA
Filing states certification does not constitute approval or issuance of a license or permit
Century Communities' board elected James Francescon, age 37, as President effective January 1, 2027, succeeding Robert J. Francescon in that role. Robert J. Francescon remains Chief Executive Officer and becomes the sole principal executive officer, while Executive Chairman Dale Francescon no longer shares that title. The filing discloses a $750,000 base salary and a promotional award of 35,008 restricted stock units for James Francescon, and it reports no financial results.
Base salary of $750,000 and a target annual bonus of at least 200% of base salary, effective January 1, 2027.
Promotional RSU award of 35,008 shares, granted November 4, 2026, vesting in three equal annual installments.
Robert J. Francescon becomes sole principal executive officer; James Francescon is his son and Dale Francescon's nephew.
Company announced the promotion in a press release dated November 9, 2026, as part of its succession planning.
Coursera's board adopted a limited-duration stockholder rights plan, effective immediately, in response to a stockholder that its recent filings show owns about 14.7% of the common stock. The plan is designed to trigger if any person or group acquires 15% or more without board approval, which would dilute that holder's stake and could deter open-market accumulation.
The board declared a dividend of one preferred share purchase right per common share, payable November 19, 2026 to holders of record on that date.
Each right allows purchase of one one-thousandth of a preferred share for $19.50, becoming exercisable only after a person or group acquires 15% or more.
The rights expire November 7, 2027, and the board may redeem them for $0.01 per right before any person becomes an acquiring person.
The Certificate of Designations was filed with the Delaware Secretary of State on November 9, 2026.
Faeth Therapeutics filed a November 9, 2026 corporate presentation with topline results from its single-arm Phase 2 PIK-201 trial of PIKTOR plus paclitaxel in advanced endometrial cancer. The filing says the results are preliminary and that PIKTOR is investigational and not approved, so the data does not yet establish a commercial outlook for shareholders.
Confirmed objective response rate of 33% (12 of 36 efficacy-evaluable patients), with a 10.30.26 efficacy data cut
Preliminary median progression-free survival of 7.4 months (95% CI 5.3, not reached) across 42 treated patients
27 of 42 patients (64%) had a grade 3 or higher treatment-related adverse event, per the 10.23.26 safety data cut
SS&C Technologies completed a private offering of $1.2 billion of 2.75% convertible senior notes due December 1, 2031, including a $150 million option exercised in full by the initial purchasers. The company plans to use the proceeds for capped call transactions, share repurchases of about $100 million, and redeeming its $2.0 billion of 5.500% Senior Notes due 2027, which adds debt and creates potential dilution if the notes convert.
Notes issued November 6, 2026 under an indenture with Wilmington Trust, National Association, as trustee, bearing interest at 2.75% payable June 1 and December 1.
Initial conversion price of about $99.46 per share, a premium of about 25.0% over the $79.57 closing price on November 4, 2026.
Proceeds planned for about $99 million capped call cost, about $100 million of share repurchases (about 1.3 million shares), and redemption of the $2,000.0 million 2027 Senior Notes.
Company may not redeem the notes before December 5, 2029, except in a cleanup redemption.
Sonoco said CEO R. Howard Coker will retire as director, president and chief executive officer effective December 31, 2026. The board named Ernest D. Haynes III, the company's president of Global Consumer Packaging, to succeed him as CEO and as a director on that date.
Coker's retirement is effective December 31, 2026; the board accepted his notice dated November 6, 2026.
Haynes, who joined Sonoco in 1997, has an annual base salary of $1,100,004 and a bonus target of 120% of salary.
CFO Paul Joachimczyk received a $1,500,000 restricted stock unit retention award that cliff vests on the second anniversary of the grant date.
Sonoco leadership, including Coker, Haynes and Joachimczyk, will present at an R.W. Baird conference webcast on November 10, 2026, starting 7:20 a.m. Central Time.
Vistagen reported constructive FDA feedback from a Type C meeting on registrational paths for its lead product candidate, fasedienol, in social anxiety disorder. The company plans to use interim assessments, submit a revised protocol, and focus development on the general SAD population rather than acute treatment alone.
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study.
Vistagen plans to add interim assessments using eDiaries and qualitative patient surveys and to submit a revised protocol to the FDA.
The company plans to pursue fasedienol for overall, not only acute, treatment of SAD, and cited the FDA's recognition of its reported safety profile.
The filing contains no financial results, and the company states that future FDA feedback may not lead to a successful registrational pathway.
OneMedNet said year-to-date bookings reached approximately $18.76 million as of November 6, 2026, with $1.388 million converted to revenue through September 30, 2026. The company also reported that contracted demand is nearly 14 times its full-year 2025 bookings and that roughly half of its 2026 contracts come from new customers, while providing fourth-quarter 2026 guidance without figures in the filing text.
Year-to-date bookings: approximately $18.76 million as of November 6, 2026
Revenue converted from bookings: $1.388 million through September 30, 2026
Contracted demand is nearly 14 times full-year 2025 bookings
Roughly half of 2026 contracts are from new customers
LKQ Corporation said Salvatore A. Abbate will become President and Chief Executive Officer and join the Board effective November 9, 2026, earlier than the previously announced December 15, 2026 start date. The change ends the interim Office of the CEO led by Chairman John Mendel and Audit Committee Chair Sue Gove, which had overseen operations since October 23, 2026.
Abbate's start date moved from December 15, 2026 to November 9, 2026
Abbate becomes principal executive officer for SEC rules on November 9, 2026
Interim Office of the CEO, Mendel and Gove, which oversaw operations since October 23, concludes
Chairman Mendel said the Board has full confidence in Abbate
The merger between Mentari Therapeutics and InMed Pharmaceuticals closed on November 9, 2026, and the combined company now trades on the Nasdaq Capital Market as MTRI under the name Mentari Therapeutics, Inc. The closing included private placements with about $490 million in gross proceeds, which the company says provide runway into 2029, and the filing puts outstanding shares at about 58.3 million. The filing contains no revenue, profit, or guidance figures, so the financial effect on shareholders is defined mainly by the new capital and share count.
Private financings totaled about $490 million in gross proceeds, led by Fairmount, including conversion of $50.0 million of previously issued convertible notes plus accrued interest.
About 58.3 million shares of common stock and equivalents are outstanding after the reverse stock split, financings, and merger.
Shares began trading on Nasdaq Capital Market under the ticker MTRI on November 9, 2026.
Todd Shegog joined the Board and will chair the Audit Committee.
CNH Industrial agreed to form a joint venture with Kobelco Construction Machinery by selling a 70% interest in its Construction Equipment business for $700 million in cash, based on an agreed enterprise value of $1 billion. CNH will keep a 30% stake and says it expects to use the net cash proceeds to reduce debt, but the deal requires regulatory approvals and is expected to close by the end of 2027.
Buyers pay $700 million in cash for 70% of the business, valued at an enterprise value of $1 billion, subject to adjustments
CNH retains a 30% interest in the joint venture, with a three-year lock-up period for each party
Closing is expected by the end of 2027; either party may terminate if closing has not occurred by March 30, 2028
CNH said it will report its 2026 third quarter earnings in a separate announcement the same day
SiriusXM announced that Board director Anjali Sud, current CEO of Tubi, will become Chief Executive Officer on January 1, 2027, succeeding Jennifer C. Witz, who steps down as CEO and board member at the end of December 31, 2026. Sud's employment agreement sets a $2,600,000 base salary, a target bonus of two times salary, and equity awards including a $10,000,000 sign-on grant, which shareholders can track in the filing.
Anjali Sud, 43, becomes CEO effective January 1, 2027, and will remain on the Board
Sud's employment agreement sets a $2,600,000 base salary and a target bonus equal to two times base salary
Sud's package includes a $10,000,000 sign-on RSU grant and $4,500,000 in time-based and $4,500,000 in performance-based RSUs
Witz will serve as an advisory consultant from January 1, 2027 through December 31, 2027 at $175,000 per month
Former CEO Dr. Andrew Regan, writing on behalf of Corvus Capital Limited, told the Board in a November 5, 2026 letter that Corvus intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share, a 96.3% premium on a post-split basis to the November 4, 2026 closing price, absent a Board proposal. The Board intends to form a special committee of independent directors with full authority over the proposal, but the committee has received no definitive terms and has made no decision, and there is no assurance any transaction will result.
Letter dated November 5, 2026, from Dr. Andrew Regan, former CEO, as a significant stockholder, on behalf of Corvus Capital Limited
Proposed price of $2.00 per share, a 96.3% premium to the November 4, 2026 closing price, on a post-split basis
Board intends to form a special committee of independent directors with full authority to consider and vote on the proposal
No definitive terms received and no decision made; the company does not commit to provide updates
In the week of November 2 to November 8, 2026, Strategy reported $283.8 million in net proceeds from sales of its MSTR Class A common stock under its at-the-market program, and used $81.9 million of those proceeds to buy 1,036 bitcoin. It also spent $188.3 million repurchasing STRC preferred stock and held $146.2 million in USD Cash as of November 8.
MSTR common stock sales: 2,051,348 shares, $283.8 million net proceeds, with $18.3 billion still available for issuance
Bitcoin: 1,036 bitcoin bought for $81.9 million; aggregate holdings reached 850,364 bitcoin at an average purchase price of $75,456
STRC preferred repurchases: 1,887,464 shares for $188.3 million; $560.3 million remains under the preferred repurchase program
USD Reserve stood at $4.77 billion as of November 8, 2026, after $21.1 million was used for preferred dividends
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.